



Patented Medicine
Prices
Review Board
Since 1987

PMPRB COMMUNIQUE

OTTAWA, June 9, 2009: The Board has released its revised Excessive Price Guidelines following extensive consultations with stakeholders.

The review of the Board's Guidelines was initiated in 2005 to ensure that the policies, guidelines and procedures the PMPRB employs to fulfill its regulatory mandate are relevant and appropriate, and are consistent with the principles of fairness, transparency, openness and predictability.

Throughout the Guidelines review process, the Board engaged in an unprecedented level of consultations with all interested stakeholders, including industry, federal, provincial and territorial governments, consumer and patient advocacy groups, third party payers, and others. In his message, the Chairman of the Board stated that the "Guidelines review exercise covered a broad range of issues, each with a significant level of complexity, and the Board appreciates the considerable effort stakeholders have taken to be active participants in the consultations over the last four years."

The Compendium of Policies, Guidelines and Procedures is available on the PMPRB Web site under Legislation, Regulations and Guidelines.

The mandate of the Patented Medicine Prices Review Board is to ensure that prices charged by patentees for patented medicines sold in Canada are not excessive; and, to report on pharmaceutical trends of all medicines, and on R&D spending by pharmaceutical patentees.

Reference: Sylvie Dupont, Director, Board Secretariat and Communications
Tel: (613) 954-8299; Toll-Free: 1 877 861-2350;
E-mail: sylvie.dupont@pmprb-cepmb.gc.ca